Archaeologists uncover massive number of horse skeletons at 'important' Roman military site
Archaeologists recently announced the discovery of over 100 buried horses dating back to ancient Rome – but the skeletons weren't found in Italy.
The excavation took place at Bad Cannstatt, a borough in southwestern Germany, said an April 16 press release from the Baden-Württemberg State Office for Monument Preservation (LAD).
The statement, translated from German to English, noted the town was one of the region's "most important Roman military sites" in ancient times. A cavalry unit there boasted around 700 horses at its peak.
Pictures from the site show horse skeletons buried in the soil as excavators worked to clear them.
The excavation began last July, spurred by recent construction projects that "necessitated archaeological investigations," according to LAD.
Experts say the remains are just under 2,000 years old, dating back to the second century A.D.
"The first horse bones discovered were dated to the second century using the radiocarbon method," said Sarah Roth, an archaeologist at LAD.
"Based on the archaeological and historical knowledge of Roman Bad Cannstatt, the horses can be attributed to the cavalry unit - a so-called 'Ala' - stationed at Hallschlag from around 100 to 150 AD."
She also noted that "the troop of nearly 500 riders likely had a total horse stock of at least 700 animals, with losses needing constant replacement."
The horses were buried roughly a quarter of a mile away from the cavalry fort and one-eighth of a mile away from civilian residences.
"The carcasses were usually dragged individually into shallow pits, where they were buried lying on their side with legs extended or bent," LAD explained in the statement.
"The site was likely marked above ground. Despite a sometimes dense arrangement, there were few overlaps of the pits."
Roth added that the horses did not appear to die during a single event, such as a battle.
Rather, the animals were probably ill or injured when they were buried, or may have been otherwise unfit for military service.
"If the horse could still walk, it would have been brought to the horse cemetery and killed on site to avoid transporting the heavy carcass," she said.
Archaeologists believe the cemetery site was more extensive than the construction site itself, but its exact size is unknown.
There have been several ancient Roman grave discoveries in the past year.
Interestingly, some horses were buried together with items, perhaps as tokens for the journey to the afterlife.
One animal was found with two jugs and a small oil lamp, and the items were "placed in the crook of its arm as a farewell."
"Here we see a particularly close bond between the owner and his horse," Roth said. "Even after around 1800 years, the grief over the death of this one animal is still evident."
There have been several ancient Roman grave discoveries in the past year.
In Vienna, Austria, archaeologists recently uncovered a mass grave containing the remains of Roman soldiers and Germanic tribesmen under a soccer field.
Earlier this year, a remarkably well-preserved dog was found at an ancient Roman site in Belgium, highlighting the prevalence of animal sacrifice in antiquity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
21 hours ago
- New York Post
Dog's ashes among dozens to rocket into orbit this weekend
Bone voyage! A beloved dog named Franz will take his final leap this weekend — into Earth's orbit. The yellow labrador's ashes will be on board the inaugural Perseverance Flight from Texas-based Celestis Inc., which is scheduled to launch around 5:30 p.m. Sunday from Vandenberg Space Force Base in Santa Barbara, CA. 4 Franz was like a sibling to Elizabeth Moore before he died at age 13 in October 2020. Celestis, Inc Carrying a total of 166 titanium and aluminum capsules, each about a quarter to a half-inch in size and filled with DNA or cremated remains, the 23-foot-tall SpaceX Falcon 9 rocket will take two trips around Earth's low orbit at a mind-boggling 17,000 mph. The space flight will last about three hours before the rocket — still carrying its priceless payload — re-enters the atmosphere and lands in the Pacific Ocean somewhere between Alaska and Hawaii, according to Celestis CEO and co-founder Charles Chafer. A recovery ship, which was already out at sea Friday in anticipation of the launch, 'will track the incoming rocket, hopefully get a visual on it, and then go pick it up out of the ocean,' Chafer explained. 4 The Texas-based company Celestis Inc.'s inaugural Perseverance Flight will take two trips around Earth's Lower Orbit after blastoff on Sunday. The capsules will first be transported to Germany, then, within two months, distributed back to the families, who each paid a whopping $3,500 to send their loved one to the stars. While the price to send Franz on the voyage was 'a lot more' than the pooch itself, his owner, Harvin Moore, said with a laugh, it was only fitting for the 'space-fanatic' Moore family to send the pup beyond the stratosphere. 'He was the best dog, just so soft and nice and loved hugs,' recalled Moore, 60, who lives in Dripping Springs, Texas, just outside Austin. 4 The Moore family can't wait to watch their beloved pooch go galactic. Celestis, Inc Franz, who was 13 when he died in October 2020, was more like a sibling than a pet to Moore's now 26-year-old daughter, Elizabeth, and son, Quinn, 21, he said. Now, the family can't wait to watch the good boy go galactic. 'The emotional power of being with a group of people who are celebrating the life of a loved one in this way … it's amazing. It's nothing we'll ever forget,' said Moore. 'It's just pure joy.' 4 The Perseverance Flight will carry a total of 166 titanium and aluminum capsules, ranging in size from a quarter to a half-inch, filled with DNA or cremated remains. Celestis, Inc 'Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy,' Chafer said. The cremated remains of Wesley Dreyer — an aerospace engineer who helped investigate the cause of the Space Shuttle Challenger's shocking explosion after takeoff on Jan. 28, 1986 — will also be on board the Perseverance Flight, as well as DNA from a living, 3-year-old German boy.
Yahoo
a day ago
- Yahoo
Vera C. Rubin debut images: How to see the groundbreaking space photos from the world's largest camera
When you buy through links on our articles, Future and its syndication partners may earn a commission. The new Vera C. Rubin Observatory is set to release its debut images — taken with the largest digital camera ever built — on Monday (Jun. 23). The world-first images and videos will be ultra-high-definition and will show off the observatory's highly anticipated, cutting-edge capabilities for the first time. Here's what you need to know. If you want to watch from home, a news conference will be streaming on YouTube in English and Spanish at 11:00 a.m. EDT on Monday. The link to watch is posted on the observatory's website, and is also embedded here. If you'd prefer to bask in the awe of the cosmos with friends, you may be able to attend a watch party near you — or even host one of your own. Groups will gather across the globe in planetariums and universities to admire the highly detailed images and videos as they are released. The observatory has shared links to a map of all registered watch parties, as well as a link to sign up to become a host. During the news conference, the observatory team will introduce the Rubin Observatory before showcasing the new images and discussing their significance. Watch parties may also hear from local scientists and special guests. Be sure to check out the details of a watch party before you attend to learn about any extra programming. The observatory, perched high on a mountain in the Chilean Andes, will peer at interstellar comets and dangerous asteroids, as well as larger objects, like twisting galaxies and exploding supernovas. Related: 'People thought this couldn't be done': Scientists observe light of 'cosmic dawn' with a telescope on Earth for the first time ever Inside Rubin lies the world's largest digital camera and six of the largest optical filters ever produced. Together, they allow researchers to observe different facets of the universe in many wavelengths of light and remarkably high detail. The camera will take a new high-resolution photo of the sky around every 40 seconds. The images will then be transmitted via fiber optic cables to a supercomputer in California, which will analyze the photos. When stitched together, the images can act as a time-lapse video of space, one that is planned to span 10 years. RELATED STORIES —Space photo of the week: Observatory, or alien planet? Boggle your mind with this 360-degree image —Vera C. Rubin Observatory: The groundbreaking mission to make a 10-year, time-lapse movie of the universe —3,200-megapixel camera of the future Vera Rubin Observatory snaps record-breaking 1st photos Using its groundbreaking instruments, the observatory is expected to contribute to current understanding of widely debated phenomena, including dark energy and dark matter — two components that are thought to make up a vast majority of the universe, but remain poorly understood. The new images could be the first of many that vastly improve our understanding of the cosmos. Whether you join a watch party or tune in from the comfort of your couch, these photos are not to be missed.
Yahoo
4 days ago
- Yahoo
Publication in Alzheimer's & Dementia Elucidates Multimodal Mechanism of Action Underpinning Promising New Neuromodulation Therapy for Alzheimer's
Review publication details benefits of repetitive transcranial magnetic stimulation (rTMS) on Alzheimer's, including increases in neuroplasticity and other structural and functional second order impacts on the brain Seminal publication on rTMS in Alzheimer's authored by Sinaptica scientific co-founders along with other experts in neuromodulation and Alzheimer's disease CAMBRIDGE, Mass., June 18, 2025--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer's and other primary neurodegenerative diseases, today announced that a comprehensive review article published in the peer-reviewed journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association delivers a landmark synthesis of evidence that positions repetitive transcranial magnetic stimulation (rTMS) as a scientifically grounded, non-invasive therapeutic strategy for Alzheimer's disease (AD). The publication, "The Neurobiological Foundation of Effective Repetitive Transcranial Magnetic Brain Stimulation in Alzheimer's Disease," was authored by a multidisciplinary team led by Sinaptica scientific co-founder Dr. Giacomo Koch of the Santa Lucia Foundation, University of Ferrara, and the Italian Institute of Technology. Drawing on foundational models and recent clinical and animal data, the article charts how rTMS modulates biological systems across multiple levels—molecular, cellular, synaptic, and network-wide—to address core mechanisms of neurodegeneration. "Our goal with this publication is to consolidate the preclinical and clinical findings to explain why rTMS isn't just symptomatic—it is actually disease modifying. This gives us a foundational understanding of how stimulation protocols can directly modulate neurotransmission, reduce inflammation, enhance plasticity, and even promote clearance of toxic proteins," said Giacomo Koch, MD, PhD, Sinaptica scientific co-founder, Neurologist, Professor of Physiology, University of Ferrara, and Director, Non-Invasive Brain Stimulation Laboratory, Santa Lucia Foundation. The publication reviews the evidence supporting the fundamental mechanisms of action of rTMS treatments in AD. rTMS exerts profound effects from the micro-molecular scale to the macro network-level scale. By engaging distinct pre- and post-synaptic structures within the stimulated neural network, it directly and indirectly influences various cellular and molecular components. These effects work together to stabilize and improve brain function through the following means: Strengthens Neuronal Structures - Upregulates neurotrophic factors e.g. BDNF, leading to neuronal structural changes e.g. via remodeling of dendritic spines. Strengthens Synapses - Modulates neurotransmitter circuits, both through increased production and sensitivity of dopaminergic-, glutamatergic-, and GABA-ergic pathways. Neuroinflammation - Mitigates neuroinflammation by reducing microglial activation and pro-inflammatory cytokines release e.g. by promoting glutamate reuptake. Amyloid - May counteract beta amyloid overproduction and toxic aggregation by interrupting a vicious cycle of hyperexcitability. Tau - Potentially reduces tau hyperphosphorylation and accumulation via the GSK-3β pathway. Clearance - Potentially increases glymphatic clearance of toxic proteins. All of the above mechanisms contribute to restoring network-wide excitation/inhibition imbalance, restoring LTP-like mechanisms of neuroplasticity, and enhancing large-scale connectivity. Authors of this definitive paper are Giacomo Koch (Experimental Neuropsychophysiology Lab, Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS), Emiliano Santarnecchi (Gordon Center for Medical Imaging, Mass General Research Institute; Harvard Medical School), Harald Hampel (Sorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital), Annibale Antonioni (Department of Neuroscience and Rehabilitation, University of Ferrara), and Alessandro Martorana (Memory Clinic, Department of Systems Medicine, University of Tor Vergata). "Based on this new publication, repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus in the brain's central Default Mode Network is an emerging element of precision medicine in neurology. Based on accumulating basic, translational, and clinical evidence, this standardized targeted non-invasive electro-magnetic brain stimulation will likely be part of the evolving clinical care landscape with different treatments and combinations," said co-author Dr. Harald Hampel, a leading international brain researcher and Alzheimer's disease (AD) scientist. "Further clinical studies are warranted to benefit the globally increasing population of AD patients." As the field moves toward more personalized and mechanistically distinct Alzheimer's therapies, this review provides a vital reference point for researchers, clinicians, and innovators. It supports the integration of rTMS into a precision medicine framework that could transform how providers manage Alzheimer's—potentially shifting the paradigm from reactive care to proactive, highly tailored, connectome-level intervention, including combination therapies. "We are beginning to see rTMS emerge as a safe, scalable precision medicine platform for Alzheimer's," said Emiliano Santarnecchi, PhD, co-founder of Sinaptica Therapeutics, Associate Professor of Radiology & Neurology at Harvard Medical School, as well as Director, Precision Neuroscience & Neuromodulation Program and Director, Network Control Laboratory, at Massachusetts General Hospital in Boston, MA. "This is not just about stimulating the brain—it's about rewiring disease-affected networks with intention and scientific precision." The publication establishes the translational relevance of these findings, citing Phase 1 and 2 human trials in which targeted, neuronavigated rTMS protocols have boosted memory, stabilized cognitive performance, restored functional brain connectivity, and enhanced gamma rhythm activity—key markers of brain health. These protocols, particularly those focused on the Default Mode Network (DMN), are seen as promising interventions for mild cognitive impairment and Alzheimer's. "This definitive reference illuminates an evolving paradigm shift away from simplistic linear 'nerve stimulation' toward the new and rapidly progressing field of 'network modulation," said Ken Mariash, CEO of Sinaptica Therapeutics. "This publication presents a higher order systems-level approach to how we think about and treat brain diseases. Sinaptica's nDMN therapy induces a cascade of network-wide effects that compound, ultimately restoring the exquisite balance of the networks involved in memory and cognition. In this new context, we can better understand how it was possible to achieve such strong and consistent clinical outcomes in previous Phase 2 trials in mild/moderate Alzheimer's patients. This important publication reinforces everything we're building at Sinaptica by elucidating the neurobiological mechanisms underlying our therapy and validating the importance of targeting the brain's network-level dysfunction with both precision and personalization." About the SinaptiStim® SystemThe SinaptiStim® System is an investigational new approach to treating Alzheimer's disease using non-invasive personalized precision neuromodulation. Calibrated to each individual's brain, the therapy is delivered in weekly 20-minute sessions in a recliner. The SinaptiStim system delivers safe, painless, customized neurostimulation technology targeting the Default Mode Network (DMN), an important brain network associated with episodic memory, introspection, and other cognitive functions. The technology was granted Breakthrough Device Designation by the FDA in 2022. The company is preparing for a pivotal randomized controlled clinical trial in mild-to-moderate Alzheimer's. In this trial, the treatment will be calibrated quarterly using TMS and EEG concurrently in combination with MRI-guided neuronavigation, which enables the SinaptiStim System to achieve customized precise repeatable targeting and safe-yet-effective dosage for each patient, tracking progress and adjusting over time to achieve the best possible individualized outcomes with its nDMN therapy. The pivotal trial will also be designed to determine the effects of SinaptiStim® System on several biomarkers measuring beta amyloid, phosphorylated tau, neuroinflammation, and synaptic dysfunction. About Sinaptica TherapeuticsSinaptica Therapeutics is a clinical-stage neuromodulation therapeutics company leading the development of a new class of novel personalized therapeutics to revolutionize the treatment of Alzheimer's and other primary neurodegenerative diseases. The company utilizes a patented non-invasive approach to treating Alzheimer's via precision neurostimulation of a key brain network involved in memory, the Default Mode Network. Sinaptica's scientific co-founders pioneered research on this novel approach which a growing body of evidence indicates can slow disease progression. Sinaptica's mission is to bring a safe, effective, and non-invasive neuromodulation therapy to Alzheimer's patients that can help to significantly slow the progression of cognitive, functional, and behavioral decline. Learn more at and follow us on LinkedIn and X @SinapticaTX. The SinaptiStim® System is for investigational use only. It has not been approved by the U.S. Food and Drug Administration and is not available for commercial sale in any geography. View source version on Contacts Kathryn Morris, BrightPointkathryn@ 914-204-6412 Sign in to access your portfolio
